Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue SUPPL. 1, 2002, Pages 61-70

  Nicolau, David ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; INFLUENZA VACCINE; JOSAMYCIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; PENICILLIN DERIVATIVE; PENICILLIN G; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG USE; ECONOMIC ASPECT; ERADICATION THERAPY; FINANCIAL MANAGEMENT; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT SELECTION; PREDICTION; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036732810     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf809     Document Type: Article

References (61)

1. Antibiotic resistance and prescribing practices
2. Challenges of managed care organizations in treating respiratory tract infections in an age of antibiotic resistance
3. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community
4. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996
5. Community-acquired pneumonia. Etiology, epidemiology, and treatment
6. The cost of treating community-acquired pneumonia
7. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America
8. Treatment cost of acute exacerbations of chronic bronchitis
9. Acute otitis media in the 1990s: The impact of antibiotic resistance
10. Epidemiology of otitis media during the first seven years of life in children in greater Boston: A prospective, cohort study
11. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy
12. Antibiotic resistance. Do we need new therapeutic approaches?
13. Epidemiology and mechanisms of resistance among respiratory tract pathogens
14. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
15. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae
16. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
17. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999
18. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
19. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 results from the SENTRY Antimicrobial Surveillance Program
20. The PROTEKT surveillance study: Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections
21. Optimizing antimicrobial therapy and emerging pathogens
22. Acute exacerbation of chronic bronchitis: Disease-specific issues that influence the cost-effectiveness of antimicrobial therapy
23. Minimum Inhibitory Concentration (MIC) Interpretive Standards (mg\L) for Streptococcus spp
24. Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media?
25. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
26. The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project
27. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
28. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
29. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
30. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
31. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural elements that regulate expression-a review
32. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae
33. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
34. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
35. Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections
36. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
37. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae
38. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics
39. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme
40. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
41. Molecular characterization of macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study
42. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media
43. Cefixime compared with amoxicillin for treatment of acute otitis media
44. Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estrolate, triple sulfonamide, ampicillin, erythromycin estrolate-triple sulfonamide, and with acute otitis media under two and one-half years of age
45. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia
46. Modelling and predicting clinical outcomes of antibiotic therapy
47. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome
48. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media
49. Cost-effective treatment of lower respiratory tract infections
50. Examination of healthcare resource utilization associated with the treatment of infections caused by susceptible (S) and non-susceptible (NS) isolates of Streptococcus pneumoniae (SPN)
51. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian Ciprofloxacin Health Economic Study Group
52. Drug-resistant Streptococcus pneumoniae
53. Immunization policies and vaccine coverage among adults. The risk for missed opportunities
54. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
55. Impact of antibiotic resistance and cross-resistance in the out-patient treatment of adult community-acquired pneumonia
56. Pharmacoeconomic impact of appropriate clinical pathways
57. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis
58. Model to evaluate the cost-effectiveness of different classes of antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany
59. Cost-effectiveness considerations in otitis media treatment
60. Measuring the indirect and direct costs of acute otitis media
61. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis